WP7: Improved Drug Safety - Ion Channel Screening

As a consequence of the broad hERG-related toxicity from various therapeutics, evaluation of the effect of new drugs on hERG function is now required by the Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) regulators and is a mandatory step in the development of novel pharmaceuticals. This requires high-throughput chemical library screenings employed early in development.